eftilagimod alfa

Phase 3

00%

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

Jun '27

IMMPPhase 3$39M

eftilagimod alfa Phase 3 Est. Readout

eftilagimod alfa• Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)756

Jun 2027~Estimated

00%

Competitive Landscape

0 competitors in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Drug Information

Target Indication

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Clinical Trial

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

IMMP

Immutep Limited

Related Pipeline

Breast Carcinoma

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Adenocarcinoma Breast Stage IV

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts